Maximilien X. Rehm
Ryerson University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maximilien X. Rehm.
European Neuropsychopharmacology | 2013
Juergen Rehm; Kevin D. Shield; Gerrit Gmel; Maximilien X. Rehm; Ulrich Frick
Alcohol consumption is a major risk factor for the burden of disease, and Alcohol Dependence (AD) is the most important disorder attributable to this behavior. The objective of this study was to quantify mortality associated with AD and the potential impact of treatment. For the EU countries, for the age group 15-64 years, mortality attributable to alcohol consumption in general, to heavy drinking, and to AD were estimated based on the latest data on exposure and mortality. Potential effects of AD treatment were modeled based on Cochrane and other systematic reviews of the effectiveness of the best known and most effective interventions. In the EU 88.9% of men and 82.1% of women aged 15-64 years were current drinkers; and 15.3% of men and 3.4% of women in this age group were heavy drinkers. AD affected 5.4% of men and 1.5% of women. The net burden caused by alcohol consumption was 1 in 7 deaths in men and 1 in 13 deaths in women. The majority of this burden was due to heavy drinking (77%), and 71% of this burden was due to AD. Increasing treatment coverage for the most effective treatments to 40% of all people with AD was estimated to reduce alcohol-attributable mortality by 13% for men and 9% for women (annually 10,000 male and 1700 female deaths avoided). Increasing treatment rates for AD was identified as an important issue for future public health strategies to reduce alcohol-attributable harm and to complement the current focus of alcohol policy.
Addiction | 2014
Jürgen Rehm; Shalini Kailasapillai; Elisabeth Larsen; Maximilien X. Rehm; Andriy V. Samokhvalov; Kevin D. Shield; Michael Roerecke; Dirk W. Lachenmeier
BACKGROUND AND AIMS Unrecorded alcohol constitutes about 30% of all alcohol consumed globally. The aims of this systematic review were to determine the epidemiology (occurrence, types, prevalence) of unrecorded alcohol consumption in different countries/regions, analyse the chemical composition of unrecorded alcohol and examine health outcomes caused by the consumption of unrecorded alcohol, based on either epidemiology or toxicology. METHODS A systematic search for, and qualitative analysis of, papers with empirical results on the different categories of unrecorded alcohol, based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS Unrecorded alcohol was widespread in all regions of the world. Artisanal fermented beverages and spirits were the most common categories of unrecorded alcohol globally, and were available on all continents. In India, industrially produced spirits (country spirits) were most prevalent. In Russia and countries of the former Soviet Union, surrogate alcohols complemented artisanal spirits. Cross-border shopping was the most prevalent method of obtaining unrecorded alcohol in parts of Europe. Ethanol was the most harmful ingredient of unrecorded alcohol, and health consequences due to other ingredients found in unrecorded alcohol were scarce. However, as unrecorded alcohol is usually the least expensive form of alcohol available in many countries, it may contribute to higher rates of chronic and irregular heavy drinking. CONCLUSIONS Very large amounts of alcohol are produced globally that go unrecorded. The primary harm from this kind of alcohol arises from the fact that it is typically much cheaper than licit alcohol.
European Addiction Research | 2015
Jürgen Rehm; Peter Anderson; J. Barry; P. Dimitrov; Zsuzsanna Elekes; F. Feijão; Ulrich Frick; Antoni Gual; Gerhard Gmel; Ludwig Kraus; Simon Marmet; J. Raninen; Maximilien X. Rehm; Emanuele Scafato; Kevin D. Shield; M. Trapencieris
Alcohol use disorders (AUDs), and alcohol dependence (AD) in particular, are prevalent and associated with a large burden of disability and mortality. The aim of this study was to estimate prevalence of AD in the European Union (EU), Iceland, Norway, and Switzerland for the year 2010, and to investigate potential influencing factors. The 1-year prevalence of AD in the EU was estimated at 3.4% among people 18-64 years of age in Europe (women 1.7%, men 5.2%), resulting in close to 11 million affected people. Taking into account all people of all ages, AD, abuse and harmful use resulted in an estimate of 23 million affected people. Prevalence of AD varied widely between European countries, and was significantly impacted by drinking cultures and social norms. Correlations with level of drinking and other drinking variables and with major known outcomes of heavy drinking, such as liver cirrhosis or injury, were moderate. These results suggest a need to rethink the definition of AUDs.
Bulletin of The World Health Organization | 2015
Michael Roerecke; Kevin D. Shield; Susumu Higuchi; A. Yoshimura; Elisabeth Larsen; Maximilien X. Rehm; Jürgen Rehm
Abstract Objective To refine estimates of the burden of alcohol-related oesophageal cancer in Japan. Methods We searched PubMed for published reviews and original studies on alcohol intake, aldehyde dehydrogenase polymorphisms, and risk for oesophageal cancer in Japan, published before 2014. We conducted random-effects meta-analyses, including subgroup analyses by aldehyde dehydrogenase variants. We estimated deaths and loss of disability-adjusted life years (DALYs) from oesophageal cancer using exposure distributions for alcohol based on age, sex and relative risks per unit of exposure. Findings We identified 14 relevant studies. Three cohort studies and four case-control studies had dose–response data. Evidence from cohort studies showed that people who consumed the equivalent of 100 g/day of pure alcohol had an 11.71 fold, (95% confidence interval, CI: 2.67–51.32) risk of oesophageal cancer compared to those who never consumed alcohol. Evidence from case-control studies showed that the increase in risk was 33.11 fold (95% CI: 8.15–134.43) in the population at large. The difference by study design is explained by the 159 fold (95% CI: 27.2–938.2) risk among those with an inactive aldehyde dehydrogenase enzyme variant. Applying these dose–response estimates to the national profile of alcohol intake yielded 5279 oesophageal cancer deaths and 102 988 DALYs lost – almost double the estimates produced by the most recent global burden of disease exercise. Conclusion Use of global dose–response data results in an underestimate of the burden of disease from oesophageal cancer in Japan. Where possible, national burden of disease studies should use results from the population concerned.
BMC Health Services Research | 2014
Kevin D. Shield; Jürgen Rehm; Maximilien X. Rehm; Gerrit Gmel; Colin Drummond
BackgroundAlcohol consumption has been linked to a considerable burden of disease in the United Kingdom (UK), with most of this burden due to heavy drinking and Alcohol Dependence (AD). However, AD is undertreated in the UK, with only 8% of those individuals with AD being treated in England and only 6% of those individuals with AD being treated in Scotland. Thus, the objective of this paper is to quantify the deaths that would have been avoided in the UK in 2004 if the treatment rate for AD had been increased.MethodsData on the prevalence of AD, alcohol consumption, and mortality were obtained from the Adult Psychiatric Morbidity Survey, the Global Information System on Alcohol and Health, and the 2004 Global Burden of Disease study respectively. Data on the effectiveness of pharmacological treatment and Motivational Interviewing/Cognitive Behavioural Therapy were obtained from Cochrane reviews and meta-analyses. Simulations were used to model the number of deaths under different treatment scenarios. Sensitivity analyses were performed to model the effects of Brief Interventions and to examine the effect of using AD prevalence data obtained from the National Institute for Health and Clinical Excellence.ResultsIn the UK, 320 female and 1,385 male deaths would have been avoided if treatment coverage of pharmacological treatment had been increased to 20%. This decrease in the number of deaths represents 7.9% of all alcohol-attributable deaths (7.0% of all alcohol-attributable deaths for women and 8.1% of all alcohol-attributable deaths for men). If we used lower AD prevalence rates obtained from the National Institute for Health and Clinical Excellence, then treatment coverage of pharmacological treatment in hospitals for 20% of the population with AD would have resulted in the avoidance of 529 deaths in 2004 (99 deaths avoided for women and 430 deaths avoided for men).ConclusionsIncreasing AD treatment in the UK would have led to a large number of deaths being avoided in 2004. Increased AD treatment rates not only impact mortality but also impact upon the large burden of disability and morbidity attributable to AD, as well as the associated social and economic burdens.
Journal of Addiction Research and Therapy | 2013
Kevin D. Shield; Jürgen Rehm; Maximilien X. Rehm; Gerrit Gmel; Henri-Jean Aubin
Objectives: To estimate the number of deaths due to alcohol consumption and alcohol dependence, and the number of deaths avoided if alcohol dependence treatment coverage rates had been increased in France in 2004. Methods: Alcohol-attributable deaths and the effects of increasing the coverage rate for alcohol dependence treatment were estimated for France in 2004 using alcohol-attributable fractions and simulations. Data on alcohol dependence, alcohol consumption and mortality were obtained from the Gender, alcohol and culture: an international study, the Global Information System on Alcohol and Health, and the 2004 Global Burden of Disease study respectively. Results: In France in 2004 15,282 deaths (2,998 female deaths; 12,284 male deaths) or 13.6% of all deaths (8.7% of all female deaths; 15.8% of all male deaths) of people 15 to 64 years of age were estimated to be attributable to alcohol consumption. Of these deaths, 70.3% (60.5% for females; 72.7% formales) were attributable to heavy drinking, and 61.6% (42.4% for females; 66.3% for males) were attributable to alcohol dependence. Increasing coverage of pharmacological alcohol dependence treatment (the most effective treatment for people with alcohol dependence in France) to 40% would result in an estimated reduction of 7.3% (219 deaths/year) of all female and 8.9% (1092 deaths/ year) of all male alcohol-attributable deaths. Conclusion: The burden of alcohol-attributable deaths in France is large and preventable. An increase in France of treatment coverage for alcohol dependence could reduce a large proportion of the alcohol-attributable burden of disease.
Rehm, Jürgen; Shield, K D; Rehm, M X; Gmel, Gerhard; Frick, Ulrich (2012). Alcohol consumption, alcohol dependence, and attributable burden of disease in Europe: Potential gains from effective interventions for alcohol dependence. Toronto: CAMH. | 2012
Jürgen Rehm; Kevin D. Shield; Maximilien X. Rehm; Gerhard Gmel; Ulrich Frick
Adicciones | 2013
Jürgen Rehm; Maximilien X. Rehm; Kevin D. Shield; Gerrit Gmel; Antoni Gual
The International Journal of Alcohol and Drug Research | 2013
Jürgen Rehm; Maximilien X. Rehm; Hannu Alho; Allaman Allamani; Henri-Jean Aubin; Gerhard Bühringer; Jean-Bernard Daeppen; Ulrich Frick; Antoni Gual; Nick Heather
Substance Abuse Treatment Prevention and Policy | 2013
Kevin D. Shield; Juergen Rehm; Gerrit Gmel; Maximilien X. Rehm; Allaman Allamani